Understanding how young children's immune systems respond to COVID-19 vaccination
Determinants of Early Childhood Immune Responses to SARS-CoV-2 Vaccination
This study is looking at how kids aged 6 months to 4 years respond to COVID-19 vaccines, especially comparing those who have had COVID before with those who haven't, to find the best ways to protect them from the virus.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10932147 on NIH RePORTER |
What this research studies
This research investigates how young children's immune systems, particularly those aged 6 months to 4 years, respond to COVID-19 vaccinations. It aims to understand the differences in immune responses between children who have previously been infected with SARS-CoV-2 and those who have not. By using advanced techniques like high-dimensional antibody profiling and flow cytometry, the study will characterize the immune responses to the vaccine, which could help optimize vaccination strategies for this age group. The goal is to determine the best timing and approach for vaccination to ensure effective and long-lasting protection against COVID-19.
Who could benefit from this research
Good fit: Ideal candidates for this research are children aged 6 months to 4 years who are receiving their COVID-19 vaccinations.
Not a fit: Patients outside the age range of 6 months to 4 years or those who have already completed their vaccination series may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved vaccination strategies that provide better protection for young children against COVID-19.
How similar studies have performed: Other research has shown promising results in understanding immune responses to vaccines in children, making this approach both relevant and necessary.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Prahl, Mary — University of California, San Francisco
- Study coordinator: Prahl, Mary
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.